All-Comers Versus Enrichment Design Strategy in Phase II Trials

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e31820e17cb
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

External Validity of the “All-Comers” Design: Insights From the BIOSCIENCE Trial

Clinical Research in Cardiology
MedicineCardiovascular MedicineCardiology
2016English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Bayesian Decision Theoretic Two-Stage Design in Phase II Clinical Trials With Survival Endpoint

Statistics in Medicine
EpidemiologyStatisticsProbability
2012English

Design and Inference in Phase II/III Clinical Trials Incorporating Monitoring of Multiple Endpoints.

English

Screened Selection Design for Randomised Phase II Oncology Trials: An Example in Chronic Lymphocytic Leukaemia

Trials
MedicinePharmacology
2011English

Between-Arm Comparisons in Randomized Phase II Trials

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2009English

Phase II Cancer Trials: Out of Control?

Clinical Cancer Research
Cancer ResearchOncology
2007English

Phase II Trials Powered to Detect Tumor Subtypes

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy